Nogapendekin alfa inbakicept (NAI)

DRUG4 trials

Sponsors

ImmunityBio, Inc.

Conditions

Acute Respiratory Distress Syndrome (ARDS)Community-Acquired Pneumonia (CAP)Critical IllnessHPV-Positive Oropharyngeal Squamous Cell CarcinomaHead and Neck CancerImmunoparalysisImmunosuppressionLymphopenia

Phase 1

NAI (Nogapendekin Alfa Inbakicept) Plus Standard of Care in Critically Ill Adults With Sepsis

Not yet recruitingNCT07783789

ImmunityBio, Inc.Sepsis, Septic Shock

Start: 2026-09-15End: 2027-12-13Target: 49Updated: 2026-08-26

Phase 2

NAI for Sepsis With Persistent Lymphopenia

Not yet recruitingNCT07578558

ImmunityBio, Inc.Critical Illness, Immunosuppression, Lymphopenia +2

Start: 2026-07-06End: 2027-10-04Target: 50Updated: 2026-05-11

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Not yet recruitingNCT07628062

ImmunityBio, Inc.Head and Neck Cancer, HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma

Start: 2026-07-22End: 2031-06-27Target: 70Updated: 2026-06-04

Phase 3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

WithdrawnNCT07492875

ImmunityBio, Inc.Acute Respiratory Distress Syndrome (ARDS), Community-Acquired Pneumonia (CAP), Immunoparalysis +2

Start: 2026-04-15End: 2029-12-31Updated: 2026-05-08